Structure Therapeutics Inc.

GPCRNASDAQHealthcare● Active

$36.92

$-0.66(-1.76%)

Market Cap$2.1B

P/E Ratio—

52W High$94.9

52W Low$15.8

Avg Volume897K

Open$37.47

Beta-1.42

Free Cash Flow Financials Revenue

Structure Therapeutics Inc. (GPCR) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

GPCR · free cash flow · updated Jun 8, 2026

Core FCF metrics

GPCR · FCF · TTM · margin & CAGR

Free cash flow was −$225.8M for FY2025 (fiscal year ending 2025-12-31), down 91.5% year-over-year

FY2025 Free Cash Flow−$225.8M▼ -91.5% YoY

Trailing 12M (TTM)−$159.2Mtrailing 4 quarters sum

FCF Margin——

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

GPCR · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$222.2M(4M)−$225.8M▼ 91.5%—

FY2024−$116.6M(1M)−$117.9M▼ 44.4%—

FY2023−$79.5M(2M)−$81.7M▼ 76.5%—

FY2022−$46.1M(0M)−$46.3M▼ 38.7%—

FY2021−$32.2M(1M)−$33.4M▼ 133.3%—

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

GPCR · P/FCF · FCF yield · FCF per share

Structure Therapeutics Inc. (GPCR) reported negative free cash flow of −$0.23B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

GPCR · cash flow statement · operating / investing / financing

For FY2025, Structure Therapeutics Inc. generated −$222.2M in operating cash flow and spent 4M in capital expenditures, yielding −$225.8M in free cash flow.

Operating Activities

−$222.2M

Cash from core business operations

2025-12-31

Investing Activities

+$89.8M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$762.5M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$222.2M) − |CapEx| (4M) = FCF (−$225.8M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

GPCR vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Structure Therapeutics Inc.YOU

GPCR

−$225.8M-91.5%—

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Structure Therapeutics Inc. (GPCR) reported free cash flow of −$225.8M for FY2025 (fiscal year ending 2025-12-31), down 91.5% year-over-year.

Structure Therapeutics Inc. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 6 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

GPCR free cash flow · 8 questions

Structure Therapeutics Inc. free cash flow was −$225.8M for FY2025, down 91.5% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$159.2M.

GPCR free cash flowGPCR FCFGPCR FCF 2025GPCR free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Structure Therapeutics Inc. · Structure Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026